ClinicalTrials.gg
Not yet recruitingNCT07625774RENEW-CKDUpdated Jun 4, 2026

Renal Efficacy and Safety of the Novel Oral Small-Molecule GLP-1RA HRS-7535 Evaluated in Participants With Chronic Kidney Disease

A Phase 3 interventional study of HRS-7535 and Placebo in Chronic Kidney Disease, sponsored by Shandong Suncadia Medicine Co., Ltd.. Not yet recruiting at 2 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-04.

Sponsored by Shandong Suncadia Medicine Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
3,690
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 245 studies in Renal Insufficiency, Chronic with a site in China — 94 open to participants now, 107 under way, 17 of them phase 3. Renal Insufficiency, Chronic · China.

Planned enrollment
15th of 164
3,690 · median 182
Started
2026
with 26 others
Phase 3
39 of 245
12 open now
Primary completion
2031-05
later than 100 of 106 live
Registered
229th of 245
by date
Lead sponsor
6 of 245
Shandong Suncadia Medicine Co., Ltd.

Among the 245 studies in Renal Insufficiency, Chronic with a site in China, this one is the 15th largest by planned enrollment of the 164 interventional ones that give a count, is one of 27 that started in 2026, is one of 39 in phase 3, reaches primary completion later than 100 of the 106 other live ones, and was the 229th registered.

Renal Insufficiency, Chronic

3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

94 of the 245 studies in Renal Insufficiency, Chronic with a site in China are open now. Recruiting first, the newest first:

89 more — sign in →

All 94 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 244 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 44 take children under 18; 80 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 245 studies in Renal Insufficiency, Chronic with a site in China, or all of them as a file.
02

Study summary

This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group and event-driven phase III clinical trial. The aim of this trial is to confirm the superiority of HRS-7535 over placebo in reducing the risks of renal outcomes and cardiovascular death among participants with chronic kidney disease (CKD) on the basis of standard of care

03

Conditions studied

  • Chronic Kidney Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subjects, Age ≥ 18 years at the time of signing ;
  2. Clinically diagnosed with chronic kidney disease at screening;
  3. CKD treatment plan consistent with current clinical guidelines or local standard of care;
  4. ≥ 20 mL/min/1.73 m² and UACR meeting protocol-specified criteria at screening and prior to randomization;
  5. Able and willing to provide a written informed consent;

Exclusion criteria

Exclusion Criteria:

  1. Uncontrolled severe hypertension prior to randomization (systolic blood pressure ≥ 180 mmHg and/or diastolic blood pressure ≥ 110 mmHg); or systolic blood pressure \< 90 mmHg.
  2. (BMI) \< 20 kg/m² at screening and prior to randomization.
  3. Prior history of renal transplantation, or planned renal transplantation during the trial;
  4. History or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2).
  5. History of acute or chronic pancreatitis, pancreatic injury, acute cholecystitis, or symptomatic/treatable gallbladder disease (excluding cholecystectomy recipients);
  6. Occurrence of acute kidney injury or receipt of dialysis treatment within 3 months prior to screening or randomization;
  7. Presence of severe gastrointestinal diseases within 3 months prior to screening or randomization, or a history of major gastrointestinal surgery affecting gastric accommodation or gastric emptying;
  8. Any condition deemed inappropriate for participation in this clinical trial by the investigator.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
3,690 participants (estimated)

Study arms

  • Experimental
    Group A, Participants will receive HRS-7535 tablets administered orally

    Drug: HRS-7535

  • Placebo comparator
    Group B, Participants will receive matching placebo tablets administered orally

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Time to first occurrence of any of the following renal composite endpoint events

    1. Death due to renal disease; 2. Cardiovascular death; 3. Renal replacement therapy (maintenance dialysis for at least 4 weeks or renal transplantation); 4. Sustained eGFR \< 15 mL/min/1.73 m² for at least 4 weeks; 5. Sustained decline of ≥40% in eGFR from baseline for at least 4 weeks;

    Time frame: Up to approximately 4.8 years

Secondary outcomes

  1. Annual rate of change in estimated glomerular filtration rate (eGFR) from baseline to 24 Month of treatment;

    Time frame: From baseline to Month 24

  2. Percentage change in urine albumin-to-creatinine ratio (UACR) from baseline at Month 9 of treatment;

    Time frame: At Month 9

  3. Change in systolic blood pressure from baseline at Month 9 of treatment.

    Time frame: At Month 9

  4. Time to first diagnosis of diabetes for participants without diabetes at baseline;

    Time frame: Up to approximately 4.8 years

  5. Time to first occurrence of any cardiovascular composite endpoint event (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke).

    Time frame: Up to approximately 4.8 years

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2026; primary completion for May 2031, 58 months later.

Of 104 industry-sponsored phase 3 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 49. This study's planned 58 months is above that.

Counting every sponsor, half of 145 studies reached it within 32 months; a quarter within 19 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
May 29, 2026
First posted
Jun 4, 2026
StartEst.
Jul 2026
Primary completionEst.
May 2031
CompletionEst.
Jul 2031
Last update
Jun 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07625774
Responsible party
Sponsor
First posted
Jun 4, 2026
Start date
Jul 2026 (estimated)
Primary completion
May 2031 (estimated)
Completion
Jul 2031 (estimated)
Last update
Jun 4, 2026

Study contacts

Liang Peng
Contact
liang.peng.lp1@hengrui.com
0518-82342973
Chen Xu
Contact
chen.xu@hengrui.com
0518-82342973

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Safiglipron

Start the discussion